West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates

Core Viewpoint - West Pharmaceutical Services (WST) reported quarterly earnings of $1.45 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, but down from $1.56 per share a year ago, indicating an earnings surprise of 18.85% [1] Financial Performance - The company posted revenues of $698 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.68%, and showing a slight increase from $695.4 million year-over-year [2] - Over the last four quarters, West Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - West Pharmaceutical shares have declined approximately 33.4% since the beginning of the year, in contrast to the S&P 500's decline of 8.6% [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $1.46 on revenues of $708.37 million, while the estimate for the current fiscal year is $6.16 on revenues of $2.89 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]